For research use only. Not for therapeutic Use.
SKLB-1028(CAT: I009514) is a novel oral multikinase inhibitor targeting epidermal growth factor receptor (EGFR), Fms-like tyrosine kinase 3 (FLT3), and Abelson tyrosine kinase (Abl). Its exceptional activity in models of FLT3-driven acute myeloid leukemia (AML) highlights its potential as a therapeutic agent for this aggressive malignancy. Additionally, SKLB-1028 demonstrates considerable potency in models of chronic myeloid leukemia (CML) with Abl mutants, suggesting its relevance in combating resistant forms of the disease.
| Catalog Number | I009514 |
| CAS Number | 1350544-93-2 |
| Synonyms | SKLB-1028; SKLB 1028; SKLB1028.;9-isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine |
| Molecular Formula | C24H29N9 |
| Purity | ≥95% |
| Target | EGFR inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| SMILES | CN1CCN(C2=CC=C(NC3=NC=C4N=C(NC5=CC=CN=C5)N(C(C)C)C4=N3)C=C2)CC1 |
| Reference | </br>1:Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26(8):1892-5. doi: 10.1038/leu.2012.67. Epub 2012 Mar 9. PubMed PMID: 22402607. |
